has been testing it's resistance points higher and higher over the past few months after the sudden gap-down in mid-December of last year. Sophiris Bio Inc
., a bio-pharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, has shown a recent development of their PRX302 treatment and doctors say it could serve as a viable resource
by targeting and destroying cancer ridden prostate tissue. This can only mean more money flowing into the company's pockets. I believe by the company's progress and the stocks movement in the market we could see this stock breaking it's resistance and spiking up to around 1.20-1.60 in the coming weeks.